Physician profile
Jun Lei
NPI 1366688152
$3,143.71
in general payments reported to CMS, 2019-2025
19 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $555 · 2021: $544 · 2022: $538 · 2023: $217 · 2024: $442 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $485.74 | 2019-2023 | |
| Gilead Sciences, INC. | $392.96 | 2019-2021 | |
| Lilly USA, LLC | $392.56 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $196.12 | 2019-2024 | Fasenra |
| Biohaven Pharmaceutical Holding Company Ltd. | $182.71 | 2022 | |
| Globus Medical, INC. | $165.85 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $146.24 | 2024-2025 | Voquezna |
| Amneal Pharmaceuticals LLC | $131.21 | 2024-2025 | Unithroid |
| Abbvie INC. | $118.67 | 2022-2025 | |
| Ibsa Pharma INC. | $114.20 | 2021-2024 | Licart, Flector, Tirosint |
| Merck Sharp & Dohme LLC | $111.55 | 2020-2021 | |
| Exact Sciences Corporation | $103.47 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $79.89 | 2024 | Veozah |
| Amgen INC. | $46.52 | 2025 | Repatha, Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.08 | 2022 | |
| Pfizer INC. | $24.54 | 2023 | |
| Nestle Healthcare Nutrition INC. | $18.66 | 2021 | |
| Glaxosmithkline, LLC. | $18.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Lei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.